8 recruiting, 7 completed, 4 unknown, 3 terminated. 17 Phase 2, 12 Phase 1, 3 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Ovarian Cancer Recurrent: new trials by email Literature Review of Ovarian Cancer Recurrent trials Research Report on Ovarian Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. OPB-201 - Endometrial Cancer Recurrent, Endometrial Cancer | Phase 1 | Recruiting | Outpace Bio, Inc. | 30 | 2026-06-30 | 2026-10-26 |
| RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) Secondary cytoreductive surgery, Platinum Based Chemotherapy - Ovarian Cancer Recurrent, Platinum Sensitive Ovarian Cancer | Phase 2 | Not yet recruiting | Asan Medical Center | 160 | 2025-12-15 | 2025-12-19 |
| A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer COM701, Normal Saline - Ovarian Cancer, Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Compugen Ltd | 60 | 2025-07-21 | 2026-10-06 |
| A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer OPB-101 - Ovarian Cancer Recurrent, Ovarian Cancer | Phase 1 | Terminated | Outpace Bio, Inc. | 3 | 2025-06-16 | 2026-10-26 |
| A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). Raludotatug Deruxtecan, Carboplatin, Paclitaxel - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 605 | 2025-04-15 | 2026-10-21 |
| Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer Pegylated liposomal doxorubicin plus adebrelimab with mirabegron, Pegylated liposomal doxorubicin plus adebrelimab - Ovarian Cancer Recurrent | Phase 2 / Phase 3 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 296 | 2025-03-18 | 2025-03-18 |
| Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. Disitamab Vedotin in Combination With Anlotinib Hydrochloride - Ovarian Cancer Recurrent | Early Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 5 | 2024-10-15 | 2024-10-28 |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Niraparib oral capsule, SBRT - Ovarian Cancer Recurrent | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 42 | 2024-06-20 | 2026-07-13 |
| A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB Ovarian Cancer Recurrent, Endometrial Cancer Recurrent | Recruiting | Sun Yat-sen University | 200 | 2024-04-24 | 2025-08-27 | |
| The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients Fluzopril Combined With Apatinib - Ovarian Cancer Recurrent | Not applicable | Not yet recruiting | Qilu Hospital of Shandong University | 50 | 2023-11-01 | 2023-10-26 |
| Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer M4344+Niraparib - Ovarian Cancer Recurrent | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2023-05-01 | 2026-06-05 | |
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
| Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer Longitudinal Plasma Biomarker Assessment - Ovarian Cancer, Ovarian Cancer Recurrent | Not applicable | Completed | University Medical Centre Ljubljana | 33 | 2021-10-23 | 2026-07-06 |
| Microtransplantation for Ovarian Cancer microtransplantation, HLA-mismatched donor peripheral stem cell infusion - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 60 | 2021-10-01 | 2021-10-27 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer Bevacizumab, Tocotrienol - Ovarian Cancer Recurrent | Phase 2 | Completed | Vejle Hospital | 20 | 2019-10-29 | 2025-01-03 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Niraparib - Ovarian Cancer Recurrent, Fallopian Tube Cancer | Phase 2 | Recruiting | Shanghai Gynecologic Oncology Group | 167 | 2019-10-18 | 2022-03-18 |
| Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Rintatolimod, Pembrolizumab, Cisplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Active not recruiting | Robert Edwards | 24 | 2019-01-28 | 2026-02-12 |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors SHR-1210, Famitinib - Renal Cell Carcinoma, Urothelial Carcinoma | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 265 | 2019-01-23 | 2022-07-01 |
| Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer radical surgery with HIPEC - Ovarian Cancer Recurrent | Not applicable | Unknown | Uppsala University Hospital | 10 | 2018-10-04 | 2021-10-08 |
Showing 20 of 27. Sign in to see all of them.
Ovarian Neoplasms (11) · Endometrial Neoplasms (4) · Fallopian Tube Neoplasms (3) · Uterine Cervical Neoplasms (2) · Carcinoma (1) · Carcinoma, Endometrioid (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Krukenberg Tumor (1) · Ovarian Diseases (1) · Recurrence (1) · Uterine Diseases (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases (13) · Genital Diseases, Female (13) · Genital Neoplasms, Female (13) · Neoplasms (13) · Neoplasms by Site (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Adnexal Diseases (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Gonadal Disorders (11) · Ovarian Diseases (10) · Uterine Neoplasms (4)
Carboplatin (5) · Paclitaxel (5) · liposomal doxorubicin (3) · 1-dodecylpyridoxal (2) · Bevacizumab (2) · Gemcitabine (2) · niraparib (2) · pembrolizumab (2) · AC 7700 (1) · Cisplatin (1) · EP-100 membrane-disrupting peptide (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Interferon alpha-2 (1) · Lenalidomide (1) · Maintenance (1)
Outpace Bio, Inc. (2) · ARCAGY/ GINECO GROUP (1) · Asan Medical Center (1) · Ayana Pharma Ltd., (1) · CanariaBio Inc. (1) · Compugen Ltd (1) · Elucida Oncology (1) · Esperance Pharmaceuticals Inc (1) · Institute of Cancer Research, United Kingdom (1) · InxMed (Shanghai) Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Leiden University Medical Center (1) · Merck Sharp & Dohme LLC (1) · Obstetrics & Gynecology Hospital of Fudan University (1) · Qilu Hospital of Shandong University (1)
United States (9) · China (7) · France (3) · Czechia (2) · Israel (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · India (1) · Italy (1) · Netherlands (1) · Poland (1)
Christopher Nicodemus, MD FACP (1) · Dae-Yeon Kim (1) · Dingwei Ye, MD (1) · Harald Fricke, MD, PhD (1) · Jihong Liu, PhD (1) · Judith Kroep, MD, PhD (1) · Lingying WU (1) · Marta Lomnytska, MD, PhD (1) · Rakesh J Patel, MD Pharm (1) · Rebecca C Arend, MD, MSPH (1) · Robert Edwards, MD (1)
PMID 25210017, PMID 32319233, PMID 34045232, PMID 35017154, PMID 35537782, PMID 36481736
2017 (1)